NMP-7
 | |
| Systematic (IUPAC) name | |
|---|---|
|
(9-pentylcarbazol-3-yl)-piperidin-1-ylmethanone | |
| Identifiers | |
| CAS Number | 1358039-07-2 |
| PubChem | CID 46871949 |
| ChemSpider | 27470961 |
| Chemical data | |
| Formula | C23H28N2O |
| Molar mass | 348.480 g/mol |
| |
| |
NMP-7 is a drug which acts as both a non-selective agonist of the CB1 and CB2 cannabinoid receptors, and also as a blocker of T-type calcium channels, the target of anticonvulsant drugs such as ethosuximide. NMP-7 has an agonist EC50 of 96.9nM at CB1 and 10.5nM at CB2, and an IC50 of 1.84μM for blocking Cav3.2 T-type calcium channels. In animal studies it produces potent analgesic effects in a variety of different tests.[1]
References
- ↑ You H, Gadotti VM, Petrov RR, Zamponi GW, Diaz P. Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands. Molecular Pain. 2011 Nov 17;7:89. PMID 22093952
This article is issued from Wikipedia - version of the Thursday, September 26, 2013. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.